Current information is "not sufficient" for FDA to determine the public health impact of acrylamide in foods, FDA Deputy Commissioner Lester M. Crawford, D.V.M., said in a statement.
FDA ISSUES STATEMENT ON ACRYLAMIDE IN FOODS -- Current information is "not sufficient" for FDA to determine the public health impact of acrylamide in foods, FDA Deputy Commissioner Lester M. Crawford, D.V.M., said in a statement. "FDA is unaware of any present data regarding acrylamide that would cause FDA to alter its current dietary recommendations for consumers." http://www.fda.gov/bbs/topics/NEWS/2002/NEW00817.html
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.